Skip to content

Evolus EOLS Payments Of Contingent Royalty Obligation

Payments Of Contingent Royalty Obligation at other companies

Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$0-100%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$32.8M+5.9%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$4.9B
Geron logo
GeronGERN
$3.72M+1.1%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$31.48M-19.6%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$121.63M+0.1%

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept eols:PaymentsOfContingentRoyaltyObligation.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's payments of contingent royalty obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's payments of contingent royalty obligation?
Evolus (EOLS) reported payments of contingent royalty obligation of $1.89M in Q1 2026.
How has Evolus's payments of contingent royalty obligation changed year-over-year?
Evolus's payments of contingent royalty obligation decreased by 20.0% year-over-year, from $2.37M to $1.89M.
What is the long-term trend for Evolus's payments of contingent royalty obligation?
Over 4 years (2021 to 2025), Evolus's payments of contingent royalty obligation has grown at a 19.0% compound annual growth rate (CAGR), from $3.1M to $6.2M.
What does payments of contingent royalty obligation mean?
This metric tracks cash payments made to third parties based on the achievement of specific sales or performance milestones related to licensed intellectual property. It represents a variable cost structure tied directly to the commercial success of the company's products. Investors use this to understand the ongoing royalty burden associated with the company's product portfolio.